Abstract
Both Docosahexaenoic acid (DHA) and Phosphatidylcholine (PC) have been shown to halt the pathogenesis of Alzheimer disease (AD) and vascular dementia. This study aimed to investigate the role of DHA-containing PC (DHA-PC) in the improvement of Aβ25-35-induced cognitive deficits in rats. Aβ25-35-induced AD rats were treated for 30 days with DHA-PC, which was extracted from Sthenoteuthis oualaniensis spawns. Cognitive improvement of the AD rats was detected using the Morris water maze (MWM). The results demonstrated that DHA-PC could improve the learning and memory abilities of AD rats in a dose-dependent pattern. Further analyses showed that expression of phosphorylated tau decreased, and the neuronal morphology recovered in brains of DHA-PC-treated AD rats, as compared with mock-treated AD rats. In addition, DHAPC treatment increased the activity of GSH-Px and SOD in the cortex and hippocampus of AD rats. Taken together, these data suggest that DHA-PC is able to improve the cognitive deficits in AD rats, probably through decreasing the phosphorylation of tau in the cortex and hippocampus CA1 area, and increasing the GSH-Px and SOD activities in the brain of AD rats.
Keywords: AD rats, cognitive improvement, DHA-PC, GSH-Px, Tau phosphorylation.
Current Topics in Medicinal Chemistry
Title:Docosahexaenoic Acid-Phosphatidylcholine Improves Cognitive Deficits in an Aβ23-35-Induced Alzheimer’s Disease Rat Model
Volume: 16 Issue: 5
Author(s): Mei-Hua Qu, Xiaoyun Yang, Yuming Wang, Qingjuan Tang, Hailin Han, Jia Wang, Guo- Du Wang, Changhu Xue and Zhiqin Gao
Affiliation:
Keywords: AD rats, cognitive improvement, DHA-PC, GSH-Px, Tau phosphorylation.
Abstract: Both Docosahexaenoic acid (DHA) and Phosphatidylcholine (PC) have been shown to halt the pathogenesis of Alzheimer disease (AD) and vascular dementia. This study aimed to investigate the role of DHA-containing PC (DHA-PC) in the improvement of Aβ25-35-induced cognitive deficits in rats. Aβ25-35-induced AD rats were treated for 30 days with DHA-PC, which was extracted from Sthenoteuthis oualaniensis spawns. Cognitive improvement of the AD rats was detected using the Morris water maze (MWM). The results demonstrated that DHA-PC could improve the learning and memory abilities of AD rats in a dose-dependent pattern. Further analyses showed that expression of phosphorylated tau decreased, and the neuronal morphology recovered in brains of DHA-PC-treated AD rats, as compared with mock-treated AD rats. In addition, DHAPC treatment increased the activity of GSH-Px and SOD in the cortex and hippocampus of AD rats. Taken together, these data suggest that DHA-PC is able to improve the cognitive deficits in AD rats, probably through decreasing the phosphorylation of tau in the cortex and hippocampus CA1 area, and increasing the GSH-Px and SOD activities in the brain of AD rats.
Export Options
About this article
Cite this article as:
Qu Mei-Hua, Yang Xiaoyun, Wang Yuming, Tang Qingjuan, Han Hailin, Wang Jia, Wang Guo- Du, Xue Changhu and Gao Zhiqin, Docosahexaenoic Acid-Phosphatidylcholine Improves Cognitive Deficits in an Aβ23-35-Induced Alzheimer’s Disease Rat Model, Current Topics in Medicinal Chemistry 2016; 16 (5) . https://dx.doi.org/10.2174/1568026615666150813144437
DOI https://dx.doi.org/10.2174/1568026615666150813144437 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Familial Hypercholesterolemia: Update and Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Plasma Acetylcholinesterase Activity Correlates with Intracerebral β-Amyloid Load
Current Alzheimer Research Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews New Thrombin and Factor Xa Inhibitors for Primary and Secondary Prevention of Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets Protein Chemistry of Amyloid Fibrils and Chaperones: Implications for Amyloid Formation and Disease
Current Chemical Biology Models of Change in Schizophrenia: One for All, or All for Some?
Current Psychiatry Reviews Left Anterior Temporal Lobe Sustains Naming in Alzheimers Dementia and Mild Cognitive Impairment
Current Alzheimer Research Astrocytes Exert and Control Immune Responses in the Brain
Current Immunology Reviews (Discontinued) HIV Genes Diversify in B Cells
Current HIV Research Structural Determinants of the Multifunctional Profile of Dual Binding Site Acetylcholinesterase Inhibitors as Anti-Alzheimer Agents
Current Pharmaceutical Design HIV-1-Associated Dementia During HAART Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Vaccination of Older Adults with Dementia Against Respiratory Infections
Infectious Disorders - Drug Targets Neuroprotective Properties of Erythropoietin in Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Role of Hexokinase and VDAC in Neurological Disorders
Current Molecular Pharmacology Microglial Integrity is Maintained by Erythropoietin Through Integration of Akt and Its Substrates of lycogen Synthase Kinase-3β, β-Catenin, and Nuclear Factor-κB
Current Neurovascular Research Small Artery Remodeling in Obesity and Insulin Resistance
Current Vascular Pharmacology Older Adults with Amnestic Mild Cognitive Impairment Exhibit Exacerbated Gait Slowing under Dual-Task Challenges
Current Alzheimer Research tPA in the Central Nervous System: Relations Between tPA and Cell Surface LRPs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Endocannabinoid System and Schizophrenia: Integration of Evidence
Current Pharmaceutical Design Ontologies of Drug Discovery and Design for Neurology, Cardiology and Oncology
Current Pharmaceutical Design